The card stated that "SGLT-2 inhibitors are contraindicated in patients with renal insufficiency," but this phrasing is misleading.
According to UWorld (Question ID: 16507), SGLT-2 inhibitors can reduce progression of nephropathy and albuminuria, and they are contraindicated only when the GFR is less than 30–45 mL/min/1.73 m².
Additionally, UpToDate explains: "For patients in whom HF or DKD (albuminuria [urine albumin excretion >200 mg/day] and estimated glomerular filtration rate [eGFR] <60 but ≥20 mL/min/1.73 m²) predominate, we prescribe an SGLT2 inhibitor at a dose with demonstrated kidney benefit (e.g., empagliflozin 10 mg, canagliflozin 100 mg, dapagliflozin 10 mg)."
So I think using the term "contraindicated" in this general way would affect understanding.
UpToDate link : https://www.uptodate.com/contents/initial-management-of-hyperglycemia-in-adults-with-type-2-diabetes-mellitus?search=sglt2%20inhibitors&topicRef=109245&source=see_link